Sentencing for Criminals Now Tops 625 Years
STONY BROOK N.Y., November 26, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN, “Applied DNA,” “the Company”), the leader in large-scale PCR-based DNA manufacturing, is pleased to report that SigNature DNA evidence has resulted in over 131 convictions, with sentences of 625 years to date, and many more cases in the pipeline.
The confirmed number of convictions and sentencing are received from law enforcement officers. Due to internal protocols in some European countries, we do not always receive confirmation of the outcome of criminal investigations; for that reason, we estimate the actual numbers to be significantly higher.
The crimes we help solve with the aid of our SigNature DNA products include attacks against armored car companies, whose activity is commonly known across Europe as “Cash-and-Valuables-in-Transit.” Other types of crimes whose conviction benefits from Applied DNA’s technology include theft of entire vehicles and their components, Automated Teller Machine (ATM) burglary, and theft of goods from businesses and private residences.
The longest-serving distributor of Applied DNA’s security products, SmartDNA Protection Nordic AB, recently won an award from Deloitte Sweden Technology Fast 50, who recognize the region’s fastest-growing technology companies.
Tony Benson, Managing Director EMEA, commented, “We are very active across Europe working with industry and Law Enforcement agencies to help the fight against crime using a well-known, fundamental security principle of ‘Detect, Deter, Defend’. The criminals involved range from low-level burglars to highly-organized and violent criminals with global distribution capabilities.”
One of the robberies in question was solved in part due to the discovery of dye-stained cash found in the criminal’s home. This dye contained a unique SigNature DNA tag which definitively connected the stained notes to the cash box that was stolen from unarmed security guards as they refilled cash machines.
Benson added, “Law Enforcement agencies are very satisfied with the high quality and speed of service we provide. We commit to a 10-day turnaround time from receipt of forensic samples to the issuance of an Expert Witness Report, and we always meet or exceed this commitment. For the last 3 years, our average turnaround time has been 7 days, which we believe is best-in-class by a country mile. We attribute this excellence to the professionalism and dedication of our Forensics team, led by Dr. Ila Lansky.
Dr. Lansky, Director of Forensics, added: ”We recognize the importance of providing accurate and quick service to Law Enforcement agencies, who are often up against deadlines to release suspects on bail. In some countries, suspects skip bail on a regular basis. The Expert Witness Reports we produce and support in occasional court appearances are detailed, accurate, thoroughly documented and accepted by courts around the world. DNA evidence is often featured on “Crime Scene Investigation” programs, and therefore easily explained to the layperson, facilitating its use and strength in conviction.”
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.